NCT05332626: LaBon

Lactobacillus Acidophilus and Postmenopausal Women

Completed NA Results posted Last updated 8 January 2026

What this trial tests

NA trial testing Probiotic group in Bone Loss in 90 participants. Completed in 1 July 2024.

Timeline

1 February 2022

Primary endpoint
1 July 2024

1 July 2024

Quick facts

Lead sponsor	Poznan University of Life Sciences
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	90
Start date	1 February 2022
Primary completion	1 July 2024
Estimated completion	1 July 2024
Sites	1 location across Poland

Drugs / interventions tested

• Probiotic group
• Placebo group

Conditions studied

• Bone Loss — all drugs for Bone Loss →
• Post Menopausal Osteoporosis — all drugs for Post Menopausal Osteoporosis →
• Mineralization — all drugs for Mineralization →

Sponsor

Poznan University of Life Sciences

Who can join

Adults 45 to 70, female only, with Bone Loss or Post Menopausal Osteoporosis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Calcium Primary · 2 years

measure the calcium concentration in serum and hair

Group	Value	95% CI
Probiotic Group	1.88	± 0.44
Placebo Group	2.04	± 0.09

DXA Primary · 2 years

bone densitometry analysis

Group	Value	95% CI
Probiotic Group	1.12	± 0.12
Placebo Group	1.15	± 0.11

Body Mass Secondary · 2 years

measure body mass in kilograms

Group	Value	95% CI
Probiotics Group	72.22	± 15.21
Placebo Group	73.88	± 13.45

Calcium Intake Secondary · 2 years

assessing calcium intake with the questionnaire

Group	Value	95% CI
Probiotics Group	1,115.81	± 529.76
Placebo Group	894.72	± 381.84

Biomarkers of Bone Turnover: CTX Secondary · 2 years

measure the concentration of C-terminal telopeptide of type I collagen (CTX) in serum

Group	Value	95% CI
Probiotics Group	5.67	± 0.52
Placebo Group	5.11	± 0.52

Biomarkers of Bone Turnover: TRAP5b Secondary · 2 years

measure the concentration of tatrate-resistant acid phosphatase isoform-5b (TRAP5b) in serum

Group	Value	95% CI
Probiotics Group	26.09	± 9.31
Placebo Group	21.13	± 6.33

Biomarkers of Bone Resorption: BSAP Secondary · 2 years

measure the concentration of bone-specific alkaline phosphatase (BSAP) in serum

Group	Value	95% CI
Probiotics Group	10.90	± 1.56
Placebo Group	11.38	± 1.96

Biomarkers of Bone Resorption: PINP Secondary · 2 years

measure the concentration of N-terminal propeptide of type I procollagen (PINP) in serum

Group	Value	95% CI
Probiotics Group	2.64	± 0.52
Placebo Group	2.66	± 0.52

Sponsor's own description

This study aims to evaluate the effect of Lactobacillus acidophilus supplementation on calcium status and bone densitometry in postmenopausal women in a randomized, double-blind placebo-controlled study.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeting strategies for bone diseases: signaling pathways and clinical studies.
   Xu H, Wang W, Liu X, Huang W, et al · · 2023 · cited 97× · PMID 37198232 · DOI 10.1038/s41392-023-01467-8
2. Effects of daily probiotic supplementation with <i>Lactobacillus acidophilus</i> on calcium status, bone metabolism biomarkers, and bone mineral density in postmenopausal women: a controlled and randomized clinical study.
   Harahap IA, Moszak M, Czlapka-Matyasik M, Skrypnik K, et al · · 2024 · cited 14× · PMID 39010860 · DOI 10.3389/fnut.2024.1401920
3. The Link Between the Gut Microbiome and Bone Metastasis.
   Sevcikova A, Martiniakova M, Omelka R, Stevurkova V, et al · · 2024 · cited 5× · PMID 39596154 · DOI 10.3390/ijms252212086
4. Nutraceuticals in osteoporosis prevention.
   Roseti L, Borciani G, Grassi F, Desando G, et al · · 2024 · cited 3× · PMID 39416651 · DOI 10.3389/fnut.2024.1445955